Michetti P, Peppercorn M A
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Gastroenterol Clin North Am. 1999 Jun;28(2):353-70, viii. doi: 10.1016/s0889-8553(05)70060-1.
A pluridisciplinary approach that integrates medical therapy with surgery and other aspects of patient care, such as nutritional and psychosocial support, is essential to the management of patients with inflammatory bowel disease (IBD). Despite new medical therapies, such as 5-amino-salicylic acid compounds, steroids, and immunomodulators, the treatment of patients with IBD remains challenging. Success depends on the appropriate use of the available medications in relation to the severity and localization of the disease. The introduction of novel immunomodulating agents such as antitumor necrosis factor alpha is likely to have a major influence on the current therapeutic strategies. This article describes the use of the available medications in the most common clinical presentations of IBD.
一种将药物治疗与手术以及患者护理的其他方面（如营养和心理社会支持）相结合的多学科方法，对于炎症性肠病（IBD）患者的管理至关重要。尽管有新的药物治疗方法，如5-氨基水杨酸化合物、类固醇和免疫调节剂，但IBD患者的治疗仍然具有挑战性。治疗的成功取决于根据疾病的严重程度和部位合理使用现有药物。新型免疫调节药物如抗肿瘤坏死因子α的引入可能会对当前的治疗策略产生重大影响。本文描述了现有药物在IBD最常见临床表现中的应用。
